CONNIE BARKER: Open Payments
NPI 1184628638 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$194 in 10 payments from 7 companies in 2025. Trend: 2023 $388 · 2024 $240 · 2025 $194
Food & beverage: $194
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 2 | $39 |
| Novo Nordisk Inc | 2 | $34 |
| GlaxoSmithKline, LLC. | 1 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Merck Sharp & Dohme LLC | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
Products named: Veozah, TRELEGY ELLIPTA, ZORYVE, Wegovy, CAPLYTA, GARDASIL 9, AIRSUPRA, Ozempic.
Industry payments across TX — which companies pay providers there.
